Total Valuation
Kyntra Bio has a market cap or net worth of CHF25.97M. The enterprise value is -CHF38.76.
Market CapCHF25.97M
Enterprise Value-CHF38.76
Share Statistics
Kyntra Bio has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders3.37%
Owned by Institutions10.45%
Financial Efficiency
Kyntra Bio’s return on equity (ROE) is -6.11 and return on invested capital (ROIC) is -50.72%.
Return on Equity (ROE)-6.11
Return on Assets (ROA)1.53
Return on Invested Capital (ROIC)-50.72%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee189.41K
Profits Per Employee5.40M
Employee Count34
Asset Turnover0.05
Inventory Turnover0.15
Valuation Ratios
The current PE Ratio of Kyntra Bio is 0.1. Kyntra Bio’s PEG ratio is -0.00002.
PE Ratio0.1
PS Ratio5.51
PB Ratio-1.18
Price to Fair Value-1.18
Price to FCF-7.38
Price to Operating Cash Flow-0.81
PEG Ratio-0.00002
Income Statement
In the last 12 months, Kyntra Bio had revenue of 6.44M and earned 183.45M in profits. Earnings per share was 45.37.
Revenue6.44M
Gross Profit5.88M
Operating Income-45.90M
Pretax Income-58.29M
Net Income183.45M
EBITDA-57.55M
Earnings Per Share (EPS)45.37
Cash Flow
In the last 12 months, operating cash flow was -38.05M and capital expenditures -9.00K, giving a free cash flow of -38.06M billion.
Operating Cash Flow-38.05M
Free Cash Flow-38.06M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Kyntra Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Kyntra Bio upcoming earnings date is Nov 9, 2026, After Close (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 9, 2026
Ex-Dividend Date―
Financial Position
Kyntra Bio as a current ratio of 3.39, with Debt / Equity ratio of 0.00%
Current Ratio3.39
Quick Ratio3.26
Debt to Market Cap0.00
Net Debt to EBITDA0.83
Interest Coverage Ratio-5.24
Taxes
In the past 12 months, Kyntra Bio has paid -90.00K in taxes.
Income Tax-90.00K
Effective Tax Rate<0.01
Enterprise Valuation
Kyntra Bio EV to EBITDA ratio is 0.22, with an EV/FCF ratio of 2.57.
EV to Sales-1.92
EV to EBITDA0.22
EV to Free Cash Flow2.57
EV to Operating Cash Flow2.59
Balance Sheet
Kyntra Bio has CHF91.32M in cash and marketable securities with CHF0.00 in debt, giving a net cash position of CHF91.32M billion.
Cash & Marketable SecuritiesCHF91.32M
Total DebtCHF0.00
Net CashCHF91.32M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF1.11
Margins
Gross margin is 18.15%, with operating margin of -712.66%, and net profit margin of 2848.63%.
Gross Margin18.15%
Operating Margin-712.66%
Pretax Margin-905.19%
Net Profit Margin2848.63%
EBITDA Margin-893.57%
EBIT Margin-905.19%
Analyst Forecast
The average price target for Kyntra Bio is CHF31.87, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF31.87
Price Target Upside― Downside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―